These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1715034)

  • 1. Lack of neurotoxicity after intra-raphe micro-injections of MDMA ("ecstasy").
    Paris JM; Cunningham KA
    NIDA Res Monogr; 1990; 105():333-4. PubMed ID: 1715034
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA).
    Paris JM; Cunningham KA
    Brain Res Bull; 1992 Jan; 28(1):115-9. PubMed ID: 1347247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys.
    Insel TR; Battaglia G; Johannessen JN; Marra S; De Souza EB
    J Pharmacol Exp Ther; 1989 Jun; 249(3):713-20. PubMed ID: 2471824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats.
    Scanzello CR; Hatzidimitriou G; Martello AL; Katz JL; Ricaurte GA
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1484-91. PubMed ID: 7680719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA.
    Steele TD; Brewster WK; Johnson MP; Nichols DE; Yim GK
    Pharmacol Biochem Behav; 1991 Feb; 38(2):345-51. PubMed ID: 1676172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term neurochemical effects of methylenedioxymethamphetamine in the rat.
    Schmidt CJ
    NIDA Res Monogr; 1989; 94():179-95. PubMed ID: 2575224
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA).
    Steele TD; Katz JL; Ricaurte GA
    Brain Res; 1992 Sep; 589(2):349-52. PubMed ID: 1382813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration.
    Johnson MP; Nichols DE
    Pharmacol Biochem Behav; 1989 May; 33(1):105-8. PubMed ID: 2476831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
    Schmidt CJ
    J Pharmacol Exp Ther; 1987 Jan; 240(1):1-7. PubMed ID: 2433425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans.
    Ricaurte GA
    NIDA Res Monogr; 1989; 94():306-22. PubMed ID: 2575227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
    Johnson M; Stone DM; Bush LG; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Feb; 161(2-3):181-8. PubMed ID: 2470597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional distribution to recovery of 5-HT levels after administration of "atrophins" MDMA and D,L-fenfluramine. Stereospecificity and comparison with 5,7-dihydroxytryptamine.
    Lehmann J; DeSouza EB; Culp S; Zaczek R
    Ann N Y Acad Sci; 1992 May; 648():291-5. PubMed ID: 1379013
    [No Abstract]   [Full Text] [Related]  

  • 15. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate.
    Slikker W; Holson RR; Ali SF; Kolta MG; Paule MG; Scallet AC; McMillan DE; Bailey JR; Hong JS; Scalzo FM
    Neurotoxicology; 1989; 10(3):529-42. PubMed ID: 2576304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat.
    Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment for neurotoxic effects.
    Gaylor DW; Slikker W
    Neurotoxicology; 1990; 11(2):211-8. PubMed ID: 1700346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
    Hekmatpanah CR; McKenna DJ; Peroutka SJ
    Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.
    Ricaurte GA; Forno LS; Wilson MA; DeLanney LE; Irwin I; Molliver ME; Langston JW
    JAMA; 1988 Jul; 260(1):51-5. PubMed ID: 2454332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro microdialysis: a novel technique for stimulated neurotransmitter release measurements.
    Bradberry CW; Sprouse JS; Sheldon PW; Aghajanian GK; Roth RH
    J Neurosci Methods; 1991 Jan; 36(1):85-90. PubMed ID: 1676433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.